Bio Light Headed for Biggest Gain in Month on Glaucoma Permit

Bio Light Israeli Life Sciences Investments Ltd. (BOLT) headed for its biggest gain in more than a month after the developer of drugs and medical technology said a unit got approval to market a glaucoma surgery device.

The shares advanced 2.1 percent, headed for the biggest gain since Feb. 21, to 0.197 shekel at 11 a.m. in Tel Aviv, giving the Ramat Gan, Israel-based company a market value of 35 million shekels ($9.3 million).

To contact the reporter on this story: Shoshanna Solomon in Tel Aviv at ssolomon22@bloomberg.net

To contact the editor responsible for this story: Claudia Maedler at cmaedler@bloomberg.net

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.